FindMyKOL

Audrey French, MD

Basic profile

Rush University Medical Center

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionChicago, IL · MidwestSpecialtyInfectious DiseaseFocusInfectious Disease
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2009–2025Why? →

Audrey French is an Infectious Disease physician affiliated with Rush University Medical Center. OpenAlex indexes 263 publications with 6,638 citations (h-index 41).

Overview

Scholarship

indexed output and impact (OpenAlex)
263publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

6,638citations

Citations across these publications.

41h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
9NIH grants · 2009–2025

Federally funded research awards.

View funding ↓

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Merck Sharp & Dohme LLC
    Program year202511 payments
    $2,002
  • Gilead Sciences, Inc.
    Program year20252 payments
    $140
  • Janssen Pharmaceuticals, Inc
    Program year20221 payment
    $23

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    51.6%
    Protease Inhibitor20.4%
    Prezcobix52%Symtuza19%Prezista11%Atazanavir Sulfate9%Ritonavir9%
    Part D<11 patients
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor12.5%
    Triumeq46%Emtricitabine-Tenofovir Disop22%Descovy17%Emtricitabine16%
    Part D<11 patients

    + 5 more classes in this area

  • Cardiovascular

    16.3%
    Statin5.3%
    Atorvastatin Calcium100%
    Part D<11 patients
    ACE inhibitor4.4%
    Enalapril Maleate100%
    Part D<11 patients

    + 2 more classes in this area

  • Respiratory

    13.8%
    beta2-Adrenergic Agonist6.1%
    Albuterol Sulfate Hfa100%
    Part D<11 patients
    Corticosteroid3.6%
    Fluticasone Propionate50%Qvar Redihaler50%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

9 NIH research awards on record, funded 2009–2025 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”